- Home
- TPST vs FEMY Comparison
TPST vs FEMY Comparison
Compare TPST & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- FEMY
- Stock Information
- Founded
- TPST 2011
- FEMY 2004
- Country
- TPST United States
- FEMY United States
- Employees
- TPST N/A
- FEMY N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- FEMY Medical/Dental Instruments
- Sector
- TPST Health Care
- FEMY Health Care
- Exchange
- TPST Nasdaq
- FEMY Nasdaq
- Market Cap
- TPST 33.0M
- FEMY 31.9M
- IPO Year
- TPST N/A
- FEMY 2021
- Fundamental
- Price
- TPST $6.95
- FEMY $0.91
- Analyst Decision
- TPST Hold
- FEMY Strong Buy
- Analyst Count
- TPST 3
- FEMY 3
- Target Price
- TPST $30.00
- FEMY $8.67
- AVG Volume (30 Days)
- TPST 90.3K
- FEMY 280.4K
- Earning Date
- TPST 08-07-2025
- FEMY 08-07-2025
- Dividend Yield
- TPST N/A
- FEMY N/A
- EPS Growth
- TPST N/A
- FEMY N/A
- EPS
- TPST N/A
- FEMY N/A
- Revenue
- TPST N/A
- FEMY $1,699,232.00
- Revenue This Year
- TPST N/A
- FEMY $231.84
- Revenue Next Year
- TPST N/A
- FEMY $245.28
- P/E Ratio
- TPST N/A
- FEMY N/A
- Revenue Growth
- TPST N/A
- FEMY 61.97
- 52 Week Low
- TPST $5.35
- FEMY $0.69
- 52 Week High
- TPST $30.03
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- TPST 46.97
- FEMY 50.88
- Support Level
- TPST $7.06
- FEMY $0.90
- Resistance Level
- TPST $7.64
- FEMY $0.99
- Average True Range (ATR)
- TPST 0.27
- FEMY 0.07
- MACD
- TPST 0.02
- FEMY 0.01
- Stochastic Oscillator
- TPST 31.91
- FEMY 39.48
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.